The present investigation aims to examine the diabetic potential of the plant Ficus racemosa in normal and alloxan induced diabetic rats. The bark extract with water, petroleum ether and with alcohol were screened for blood glucose lowering activity and the alcoholic extract having better therapeutic potential was prepared through Soxhlet extraction for further study. Alcoholic and aqueous extract of bark of Ficus racemosa at a dose of 400 mg/Kg was given to normal and alloxan induced diabetic rats and the blood samples taken from the retero-orbital plexus vein were analyzed for blood glucose level as per standard protocol with available kits through Auto-analyzer. The comparison of blood sugar level as per model schedule showed that in normal group the ethanolic extract, at a dose of 400 mg/Kg intra-peritoneal, the blood glucose lowering 28.66 % while in aqueous extract given group it was 25.90 %. In alloxan induced diabetic rats decrease in blood glucose level in aqueous and ethanolic extract group was found to be 27.01 % and 45.03 % respectively. In conclusion, the ethanolic extract of Ficus racemosa reflected anti-diabetic potential through its glucose lowering activity in experimental animals. It supported the folklore claim of anti-diabetic activity of the plant.

The structural requirements for decreasing cholesterol and triglyceride levels remain largely uninvestigated. Thus a systematic investigation of certain N-substituted dibenz[c,e]azepines is necessary. Nine compounds of N-substituted derivatives of Dibenz[c,e]azepine-5,7-Dione were synthesized and they were tested for antihyperlipidemic activity. Compounds synthesized (C-1, C-3, C-4 and C-5) significantly lowered the serum total cholesterol, triglyceride and LDL (low density lipoprotein) levels and also improved the HDL (high density lipoprotein) level in Triton-WR 1339 induced hyperlipidemic rats. Synthesis and antihyperlipidemic activity of Dibenz[c,e]azepine-5,7-dione derivatives in Triton WR-1339-induced hyperlipidemic rats, Journal of Drug Delivery and Therapeutics. 2018; 8(2):129-135 DOI: http://dx.

No abstract

Background: Early diagnosis of HIV infection in exposed infants and children is essential component to child survival. EID, a virological DNA PCR test on dried blood spot, aims at early diagnosis and ART initiation, breast feeding choices and linkage to care. It confers substantial benefit to the infected and uninfected infants and provides a unique opportunity to evaluate the performance of PPTCT program. Materials and method: Present study conducted in the department of Obstetrics and Gynecology, NSCB Medical College, Jabalpur from March 2016 to August 2017. HIV exposed infants and children between 6 weeks to 18 months of age were included. HIV testing (DNA PCR and antibody tests) done at 6weeks, 6, 12 and 18 months as per pediatric ART guidelines of NACO, 2015. Results: Total 145 infants/children were tested during study period. 8 found to be HIV positive which gives an incidence of 5.51% in out institute.112 (80.7%) had first visit between 6 weeks to 6 months.130(89.6)% mother-baby pair received ART/ARV prophylaxis. Transmission rate lowest (0.76%) in Mother-baby pair who received ART. 69(47.9% infants were on replacement feeding. The transmission rate was (8.1%). One death observed and 12 (8.27%) lost to follow up. EID results at first contact were accurate and well correlated with the results at 6, 12 and 18 month. Conclusion: EID is a vital component of PPTCT program. It confirms the diagnosis as early as 6 weeks and confers an accurate and consistent results throughout testing protocol, thus establishing the integrity of EID. It assists in decision making on infant feeding practices.